Emcure Pharmaceuticals has announced its consolidated financial results for the fourth quarter and full year ended March 31, 2025. The company recorded robust growth, reporting a 19% year-on-year increase in revenue and a 63% rise in profit after tax (PAT) for the quarter.
The performance was driven by solid contributions from both domestic and international markets. The domestic business registered a 24.8% year-on-year growth, led by strong results in the Women’s Health and Cardiology segments, alongside accelerated momentum in Dermatology and Over-the-Counter (OTC) product categories.
International operations achieved a 15.6% increase, with the “Rest of the World” segment expanding by 39.3%. The company’s business in Canada continues to perform strongly following the integration of the Mantra acquisition. In Europe, recent product portfolio acquisitions and regulatory approvals are expected to support continued growth.
Satish Mehta, Chief Executive Officer and Managing Director of Emcure Pharmaceuticals Ltd, stated:
“Emcure delivered a strong performance in the fourth quarter with consistent growth across all business segments. Over the past year, we have effectively implemented our strategic initiatives in both domestic and international markets. Domestically, we have expanded our market coverage and strengthened our product pipeline. Internationally, our differentiated offerings are gaining regulatory approvals. Our forward strategy will emphasize margin enhancement through operational efficiencies and new product introductions.”
Emcure Pharmaceuticals Ltd is a leading Indian pharmaceutical enterprise headquartered in Pune. The company is engaged in the development, manufacture, and global marketing of a broad spectrum of pharmaceutical products. Driven by research and development, Emcure focuses on delivering differentiated therapies across key treatment areas, with a commitment to innovation, quality, and patient care.
Founded in 1981, Emcure ranks as the 12th largest pharmaceutical company in India by domestic sales as of MAT June 2024. The company operates in more than 70 countries worldwide, including significant presences in Europe and Canada.
